Loading…
Employees: 717
Size Mesa Laboratories (MLAB) is a United States Health Care company (Medical Specialties) with a market value of $718M, the 2466th largest of 3,117 United States companies the cockpit tracks. Shares closed at $128.25 on 6 Nov 2026.
Performance Over six months the shares gained 22.6%, against -9.0% for the median peer and -1.1% for the United States market (cap-weighted) — 4th highest of 21 in its peer set.
Growth Revenue grew 3.0% over the last twelve months (peer median +6.2%); the operating margin is 9.0% (peer median 13.7%).
Valuation It trades at 12.6× forward earnings against a peer median of 20.0× (5th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is +8 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points below its cost of capital (9.4% WACC).
Short interest Short interest is 7.0% of the free float (15 Oct 2026).
Next results Next results expected around 9 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $250M | $249M | $241M | $216M | $219M |
| Revenue growth | — | +3% | +11% | -1% | — |
| Gross profit | $143M | $141M | $132M | $111M | $111M |
| EBITDA | $45.4M | $41.8M | $40.9M | $36.3M | $36.5M |
| Net income | $4.80M | $6.71M | -$1.97M | -$254M | $930,000 |
| Free cash flow | $52.9M | $39.6M | $42.6M | $41.6M | $23.4M |
| Capital expenditure | $2.80M | $3.25M | $4.50M | $2.57M | $4.54M |
| Total debt | $161M | $169M | $194M | $231M | $192M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MLAB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.7% | -0.8% | 10th highest of 21 |
| 6-month return | +22.6% | -9.0% | 4th highest of 21 |
| Distance from 52-week high | -11.2% | -25.6% | 5th highest of 21 |
| Revenue growth (TTM) | +3.0% | +6.2% | 7th lowest of 21 |
| Operating margin | 9.0% | 13.7% | 10th lowest of 21 |
| Forward P/E | 12.6× | 20.0× | 5th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 21.1% | 0.1% | 3rd most demanding of 15 |
| Growth delivered (Del g) | +13.2% | +12.1% | 7th highest of 15 |
| Hurdle (Req g minus delivered) | +7.9 pp | -10.9 pp | 4th most demanding of 15 |
| ROIC minus cost of capital | -3.8 pp | +4.1 pp | 5th lowest of 21 |
| EV / EBITDA | 18.7× | 8.4× | most expensive of 7 |
| Net debt / EBITDA | 2.9× | -0.4× | 2nd most indebted of 7 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mesa Laboratories MLAB | United States | $718M | +23% | +3% | 9% | 12.6× | 21.1% | +13.2% |
| Synektik SNT.WA | Poland | $713M | +16% | +50% | 24% | 11.8× | 0.1% | +40.3% |
| SWS Hemodialysis Care 688410.SS | China | $723M | -12% | +31% | 19% | 24.1× | 16.7% | +25.9% |
| Shenzhen Sunnypol Optoelectornics 002876.SZ | China | $728M | -8% | +29% | 5% | 41.8× | 11.1% | +14.2% |
| Livsmed 491000.KS | South Korea | $706M | -47% | +89% | -59% | n/a | n/a | n/a |
| QuidelOrtho QDEL | United States | $734M | -1% | -5% | -2% | 12.0× | n/a | n/a |
| Pacific Biosciences of California PACB | United States | $701M | +60% | +2% | -102% | n/a | n/a | n/a |
| Shanghai Sanyou Medical 688085.SS | China | $700M | -21% | +15% | 4% | 50.9× | 29.1% | +6.8% |
| Shanghai Kinetic Medical 300326.SZ | China | $698M | -7% | -28% | 17% | 27.4× | 8.1% | -1.9% |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $741M | -5% | +12% | 18% | 16.1× | -2.1% | +11.8% |
| Shenzhen Lifotronic Technology 688389.SS | China | $749M | -11% | +14% | 13% | 32.4× | 13.5% | +13.3% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |
| Japan Lifeline 7575.T | Japan | $685M | +16% | +6% | 19% | 14.1× | -9.7% | +2.9% |
| Beijing Chunlizhengda Medical Instruments 688236.SS | China | $684M | -21% | -13% | 31% | 19.1× | -5.4% | +2.2% |
| Jiangsu Hanvo Safety Product 300952.SZ | China | $681M | -21% | +6% | 8% | 47.6× | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| AK Medical 1789.HK | Hong Kong | $664M | -26% | +16% | 26% | 10.8× | -11.4% | +6.7% |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |